Skip to content

Investigation of efficacy of different spinal cord stimulation paradigms for the treatment of chronic neuropathic pain

Investigation of efficacy of different spinal cord stimulation paradigms for the treatment of chronic neuropathic pain - PARS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00018929
Enrollment
60
Registered
2020-01-14
Start date
2020-04-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M54.4

Interventions

Group 1: SCS device with SCS paradigm "burst" Group 2: SCS device with SCS paradigm 1 kHz Group 3: SCS device with SCS paradigm 1.499 kHz Group 4: SCS device with SCS paradigm placebo-stimulation

Sponsors

Universitätsklinikum Heidelberg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Patients suffering from intractable neuropathic pain, who have been considered for SCS therapy according to current German treatment guidelines and, within 48 of study enrolment, were already implanted with a wireless SCS device (Stimwave®) • Placement of the distal tip of the electrode between upper level of Th8 and lower level of Th12 • leg pain > back pain • age of patient = 18 Jahre • Written consent • Duration of pain history >6 months and < 5 years

Exclusion criteria

Exclusion criteria: • Covering of the pain area with the SCS stimulation device (Stimwave®) <90% • Ischemic pain (i.e. Peripheral artery disease, angioma) • Chronic primary pain • Implantation of several SCS electrodes • Coagulopathy • Any planned changes in existing pain medication for the duration of trial participation (period of 35 days) • Pregnancy • Neurodegenerative disease • Lack of understanding of the trial and the individual consequences of participating in the trial • Expected lack of compliance (i.e. patient is not able to complete the trial questionnaires)

Design outcomes

Primary

MeasureTime frame
Self-assessment of pain perception measured on the Visual Analogue Scale (VAS)

Secondary

MeasureTime frame
Self-assessment of pain quality (as determined by Pain Detect Questionnaire), quality of life (as determined by Quality of Life EQ-5D-5L Questionnaire), anxiety perception (as determined by the Hospital Anxiety and Depression Scale) and physical restriction (as determined by the Oswestry Disability Index)

Countries

Germany

Contacts

Public ContactRezvan Ahmadi

Neurochirurgische UniversitätsklinikUniversitätsklinikum Heidelberg

Rezvan.Ahmadi@med.uni-heidelberg.de+49 6221 56-6308

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 24, 2026